Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Agomelatine versus SSRI for circadian rest/activity rhythms in major depressive disorder
ISRCTN49376288Phase 3Completed
- Sponsor
- Servier
- Start
- Apr 2005
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of agomelatine in major depressive disorder (MDD) (2 arms), sponsored by Servier. Primary endpoint: Efficacy assessed by actimetry recording. Started Apr 2005; status: completed.
02
Drugs
agomelatine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ISRCTN49376288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN49376288.